Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as New Glycogen Synthase Kinase-3β Inhibitors

2013 ◽  
Vol 56 (24) ◽  
pp. 10066-10078 ◽  
Author(s):  
Valeria La Pietra ◽  
Giuseppe La Regina ◽  
Antonio Coluccia ◽  
Valeria Famiglini ◽  
Sveva Pelliccia ◽  
...  
2019 ◽  
Vol 27 (9) ◽  
pp. 1804-1817 ◽  
Author(s):  
Natalia A. Lozinskaya ◽  
Denis A. Babkov ◽  
Ekaterina V. Zaryanova ◽  
Elena N. Bezsonova ◽  
Alexander M. Efremov ◽  
...  

Molecules ◽  
2019 ◽  
Vol 24 (12) ◽  
pp. 2331 ◽  
Author(s):  
Stanislav Andreev ◽  
Tatu Pantsar ◽  
Francesco Ansideri ◽  
Mark Kudolo ◽  
Michael Forster ◽  
...  

Glycogen synthase kinase-3β (GSK-3β) represents a relevant drug target for the treatment of neurodegenerative pathologies including Alzheimer’s disease. We herein report on the optimization of a novel class of GSK-3β inhibitors based on the tofacitinib-derived screen hit 3-((3R,4R)-3-((7-chloro-9H-pyrimido[4,5-b]indol-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile (1). We synthesized a series of 19 novel 7-chloro-9H-pyrimido[4,5-b]indole-based derivatives and studied their structure–activity relationships with focus on the cyanoacetyl piperidine moiety. We unveiled the crucial role of the nitrile group and its importance for the activity of this compound series. A successful rigidization approach afforded 3-(3aRS,7aSR)-(1-(7-chloro-9H-pyrimido[4,5-b]indol-4-yl)octahydro-6H-pyrrolo[2,3-c]pyridin-6-yl)-propanenitrile (24), which displayed an IC50 value of 130 nM on GSK-3β and was further characterized by its metabolic stability. Finally, we disclosed the putative binding modes of the most potent inhibitors within the ATP binding site of GSK-3β by 1 µs molecular dynamics simulations.


Sign in / Sign up

Export Citation Format

Share Document